Description

Product Overview

Socazolimab is a humanized monoclonal antibody specifically designed to target immune checkpoint molecules, enhancing T-cell-mediated anti-tumor responses. Its mechanism of action involves selective binding to target receptors on immune cells, modulating immune signaling pathways, and promoting tumor cell recognition and elimination.

Supplied as a high-purity solution, Socazolimab ensures accurate dosing for in vitro and in vivo preclinical studies. Bulk wholesale availability and factory customization enable cost-effective research scale-up, making it suitable for academic labs, translational research, and large-scale preclinical screening.

Mechanistic Insights

• Checkpoint Blockade: Socazolimab binds to its immune checkpoint target, preventing inhibitory signaling and restoring T-cell activity.

• T-cell Activation: Enhances proliferation and cytotoxic activity of CD8+ T-cells.

• Cytokine Modulation: Promotes Th1-type cytokine production, including IFN-γ and TNF-α.

• Tumor Microenvironment Modulation: Reduces immunosuppressive signaling, increasing antigen presentation and T-cell infiltration.

This mechanism positions Socazolimab as a key reagent for studying immune checkpoint regulation, T-cell activation, and combination immunotherapy strategies in preclinical cancer research.

Preclinical Applications

1. Immune Checkpoint Research: Evaluate T-cell activation, checkpoint blockade efficacy, and inhibitory receptor signaling.

2. Cytokine Modulation Studies: Investigate effects on Th1/Th2 balance, IFN-γ production, and TNF-α secretion.

3. Combination Immunotherapy: Co-administration with PD-1, PD-L1, CTLA-4 inhibitors, or small-molecule immunomodulators.

4. Tumor Microenvironment Analysis: Assess T-cell infiltration, immune cell activation, and immunosuppressive pathway modulation.

5. In Vivo Preclinical Models: Xenograft, syngeneic, and humanized mouse models for anti-tumor efficacy studies.

6. Bulk Wholesale and Factory Customization: Large-scale supply with verified batch-to-batch consistency, adjustable concentration, and formulation options.

Product Specifications

Socazolimab Mechanism of Action

Immune Checkpoint Inhibition

• Socazolimab selectively binds to its target receptor on T-cells, preventing inhibitory signaling.

• Restores cytotoxic activity of CD8+ T-cells and promotes T-cell proliferation.

• Enhances tumor recognition by antigen-specific T-cells.

Cytokine Modulation

• Promotes production of IFN-γ, TNF-α, and IL-2.

• Supports Th1-biased immune response.

• Reduces immunosuppressive cytokines such as IL-10 and TGF-β.

Tumor Microenvironment Effects

• Enhances infiltration of T-cells into tumors.

• Decreases regulatory T-cell (Treg) and myeloid-derived suppressor cell (MDSC) activity.

• Improves antigen presentation and dendritic cell maturation.

Combination and Resistance Studies

• Co-administration with other checkpoint inhibitors (PD-1, CTLA-4).

• Evaluation of synergy with chemotherapeutic or kinase inhibitors.

• Assessment of immune evasion mechanisms and adaptive resistance.

  

Side Effects (Preclinical Observations)

Cellular Effects

• Enhanced T-cell activation

• Cytokine release (dose-dependent, in vitro)

• Modulation of immune cell proliferation

Apoptotic Effects

• Not directly cytotoxic to non-target cells

• Indirect tumor cell killing via activated T-cell-mediated cytotoxicity

Laboratory Handling

• Handle in biosafety level 2 laboratory

• Use PPE and biological safety cabinet

• Dispose of waste according to institutional biosafety protocols

Keywords

Socazolimab, monoclonal antibody, high-purity antibody solution, immune checkpoint inhibitor, T-cell activation, cytokine modulation, tumor immunotherapy research, preclinical antibody reagent, bulk antibody, factory customization, laboratory research reagent.

Shipping Guarantee

All Socazolimab shipments are temperature-controlled and packaged to prevent contamination. International express shipping with tracking and insurance ensures product integrity.

Trade Assurance

• Purity ≥98% verified by SEC-HPLC

• CoA included for each batch

• Replacement or refund for deviations from listed specifications

Payment Support

• PayPal

• Visa / MasterCard / American Express

• T/T bank transfer

• USDT / Bitcoin / Ethereum

All Socazolimab transactions encrypted and verified for confidentiality.

Disclaimer

Socazolimab (CAS 2305043-30-3) is for research purposes only. Not intended for human or veterinary use, clinical applications, or diagnostic purposes. Handle only in qualified laboratories following institutional safety guidelines. Supplier assumes no liability for misuse.

References (Clickable)

• PubChem – Socazolimab
  https://pubchem.ncbi.nlm.nih.gov/

• ChEMBL – Monoclonal Antibody Bioactivity
  https://www.ebi.ac.uk/chembl/

• DrugBank – Immunotherapy Antibodies
  https://go.drugbank.com/

• PubMed – Immune Checkpoint Inhibitor Studies
  https://pubmed.ncbi.nlm.nih.gov/

• IUPHAR/BPS Guide – Monoclonal Antibodies
  https://www.guidetopharmacology.org/